公开(公告)号：WO2012138102A2

公开(公告)日：2012-10-11

申请号：PCT/KR2012002496

申请日：2012-04-03

Applicant: KOREA RES INST OF BIOSCIENCE ,  PARK YOUNG WOO ,  JO KI WON ,  LEE DONG HEE ,  YUN SEON HA ,  SOHN MYUNG HO ,  KIM KYUNG JIN ,  KIM DONG JIN ,  LEE YOO RA ,  PARK CHAN WOONG

Inventor： PARK YOUNG WOO ,  JO KI WON ,  LEE DONG HEE ,  YUN SEON HA ,  SOHN MYUNG HO ,  KIM KYUNG JIN ,  KIM DONG JIN ,  LEE YOO RA ,  PARK CHAN WOONG

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  C12N15/13

CPC classification number: C07K14/485 ,  C07K16/28 ,  C07K2317/21

Abstract: The present invention relates to human antibodies that binds specifically to the extracellular water-soluble domain of DLK1 and fragments which include antigen-binding sites thereof; a polynucleotide which encodes for the human antibodies or fragments thereof; a recombinant vector containing the polynucleotide; transformants transformed with the recombinant vector; method for manufacturing the human antibodies or fragments thereof; a pharmaceutical composition for preventing or treating disease which includes the human antibodies or fragment thereof; and diagnostic kits. Human antibodies and fragments which include antigen-binding sites that bind specifically to the extracellular water-soluble domain of DLK1 of the present invention show anti-tumor activity. By significantly raising the binding capacity of the DLK1 extracellular water-soluble domain to the Activin receptor type II B (ACVR2B), utility is demonstrated for prevention and treatment of diseases associated with ACVR2B signal transduction including related metabolic disorders, immune disease, liver diseases, and cancer.

Abstract translation: 本发明涉及与DLK1的细胞外水溶性结构域特异性结合的人抗体和包括其抗原结合位点的片段; 编码人抗体或其片段的多核苷酸; 含有多核苷酸的重组载体; 用重组载体转化的转化体; 制造人抗体或其片段的方法; 用于预防或治疗疾病的药物组合物，其包括人抗体或其片段; 和诊断试剂盒。 包括与本发明的DLK1的细胞外水溶性结构域特异性结合的抗原结合位点的人抗体和片段显示抗肿瘤活性。 通过显着提高DLK1细胞外水溶性结构域与激活素受体IIB（ACVR2B）的结合能力，证明了预防和治疗与ACVR2B信号转导相关的疾病的效用，包括相关代谢紊乱，免疫疾病，肝脏疾病， 和癌症。

公开(公告)号：WO2010087594A3

公开(公告)日：2010-10-21

申请号：PCT/KR2010000315

申请日：2010-01-18

Applicant: KOREA RES INST OF BIOSCIENCE ,  PARK YOUNG WOO ,  JEON JAE WON ,  JUNG JOON-GOO ,  CHOI HYE IN ,  SOHN MYUNG-HO ,  KIM HO YOUN ,  CHO MI-LA ,  JANG YOUNG-SOON ,  MOON JI-HUN ,  PARK JI HYUN

Inventor： PARK YOUNG WOO ,  JEON JAE WON ,  JUNG JOON-GOO ,  CHOI HYE IN ,  SOHN MYUNG-HO ,  KIM HO YOUN ,  CHO MI-LA ,  JANG YOUNG-SOON ,  MOON JI-HUN ,  PARK JI HYUN

IPC: A61K39/395 ,  A61K31/7105 ,  A61P29/00 ,  A61P37/08 ,  G01N33/53

CPC classification number: A61K31/7105 ,  G01N33/6893 ,  G01N2333/70596

Abstract: The present invention relates to an anti-inflammatory composition using an antibody specifically binding to CD93 or a soluble fragment thereof, a method for diagnosing inflammatory diseases using an aptamer or an antibody specifically binding to CD93 or a soluble fragment thereof, and a kit for diagnosing inflammatory diseases.

Abstract translation: 本发明涉及使用特异性结合CD93的抗体或其可溶性片段的抗炎组合物，使用适体或与CD93特异性结合的抗体或其可溶性片段来诊断炎性疾病的方法，以及诊断用试剂盒 炎性疾病。

公开(公告)号：WO2010032899A3

公开(公告)日：2010-07-15

申请号：PCT/KR2008006116

申请日：2008-10-16

Applicant: KOREA RES INST OF BIOSCIENCE ,  PARK YOUNG WOO ,  HOE KWANG-LAE ,  CHOI SO-YOUNG ,  PARK JI HYUN ,  SONG EUN-JUNG ,  YU JUNG ,  SOHN MYUNG-HO ,  KIM SUNGSUB ,  JANG MYEOUNG HEE ,  KIM DONG-JIN

Inventor： PARK YOUNG WOO ,  HOE KWANG-LAE ,  CHOI SO-YOUNG ,  PARK JI HYUN ,  SONG EUN-JUNG ,  YU JUNG ,  SOHN MYUNG-HO ,  KIM SUNGSUB ,  JANG MYEOUNG HEE ,  KIM DONG-JIN

IPC: C07K16/18

CPC classification number: C07K16/40 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/622

Abstract: The present invention relates to an alpha-endolase (ENO1) -specific human antibody, and more particularly to a human antibody including a complementarity determining region (CDR) and a framework region (FR) derived from a human antibody specifically bound to ENO1. The ENO1-specific human antibody expressed in the various kinds of cancer cells of the present invention may be used in diagnosis of the cancer, classification of the disease, visualization, treatment, and prognostic evaluation.

Abstract translation: 本发明涉及α-内酯酶（ENO1）特异性人抗体，更具体地涉及包含衍生自特异性结合ENO1的人抗体的互补决定区（CDR）和构架区（FR）的人抗体。 在本发明的各种癌细胞中表达的ENO1特异性人抗体可用于诊断癌症，疾病分类，可视化，治疗和预后评价。

公开(公告)号：WO2010087594A9

公开(公告)日：2011-11-10

申请号：PCT/KR2010000315

申请日：2010-01-18

Applicant: KOREA RES INST OF BIOSCIENCE ,  PARK YOUNG WOO ,  JEON JAE WON ,  JUNG JOON-GOO ,  CHOI HYE IN ,  SOHN MYUNG-HO ,  KIM HO YOUN ,  CHO MI-LA ,  JANG YOUNG-SOON ,  MOON JI-HUN ,  PARK JI HYUN

Inventor： PARK YOUNG WOO ,  JEON JAE WON ,  JUNG JOON-GOO ,  CHOI HYE IN ,  SOHN MYUNG-HO ,  KIM HO YOUN ,  CHO MI-LA ,  JANG YOUNG-SOON ,  MOON JI-HUN ,  PARK JI HYUN

IPC: A61K39/395 ,  A61K31/7105 ,  A61P29/00 ,  A61P37/08 ,  G01N33/53

CPC classification number: A61K31/7105 ,  G01N33/6893 ,  G01N2333/70596

Abstract: The present invention relates to an anti-inflammatory composition using an antibody specifically binding to CD93 or a soluble fragment thereof, a method for diagnosing inflammatory diseases using an aptamer or an antibody specifically binding to CD93 or a soluble fragment thereof, and a kit for diagnosing inflammatory diseases.

Abstract translation: 本发明涉及使用特异性结合CD93的抗体或其可溶性片段的抗炎组合物，使用特异性结合CD93或其可溶性片段的适体或抗体诊断炎性疾病的方法，以及用于诊断的试剂盒 炎性疾病。

公开(公告)号：WO2010044506A3

公开(公告)日：2010-07-15

申请号：PCT/KR2008006614

申请日：2008-11-10

Applicant: KOREA RES INST OF BIOSCIENCE ,  PARK YOUNG WOO ,  CHOI SO-YOUNG ,  JANG YOUNG-SOON ,  PARK JI HYUN ,  SONG EUN-JUNG ,  YU JUNG ,  SOHN MYUNG-HO ,  JEON JAE WON ,  JUNG JOON-GOO ,  KIM SUNGSUB ,  JANG MYEOUNG HEE

Inventor： PARK YOUNG WOO ,  CHOI SO-YOUNG ,  JANG YOUNG-SOON ,  PARK JI HYUN ,  SONG EUN-JUNG ,  YU JUNG ,  SOHN MYUNG-HO ,  JEON JAE WON ,  JUNG JOON-GOO ,  KIM SUNGSUB ,  JANG MYEOUNG HEE

IPC: C07K16/18

CPC classification number: C07K16/40 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/00 ,  C12N9/6424

Abstract: The present invention relates to a transmembrane protease, serine (TMPRSS4) -specific human antibody, and more particularly to a human antibody including a complementarity determining region (CDR) and a framework region (FR) derived from a human antibody specifically bound to TMPRSS4. The TMPRSS4- specific human antibody expressed in the various kinds of cancer cells of the present invention may be used in diagnosis of the cancer, classification of the disease, visualization, treatment, and prognostic evaluation.

Abstract translation: 本发明涉及跨膜蛋白酶，丝氨酸（TMPRSS4） - 特异性人抗体，更具体地涉及包含衍生自特异性结合TMPRSS4的人抗体的互补决定区（CDR）和构架区（FR）的人抗体。 在本发明的各种癌细胞中表达的TMPRSS4特异性人抗体可用于诊断癌症，疾病分类，可视化，治疗和预后评估。

公开(公告)号：WO2010061991A1

公开(公告)日：2010-06-03

申请号：PCT/KR2008/007045

申请日：2008-11-28

Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY ,  PARK, Young Woo ,  CHOI, So-Young ,  SONG, Eun-Jung ,  YU, Jung ,  SOHN, Myung-Ho ,  JEON, Jae Won ,  JUNG, Joon-Goo ,  JANG, Myeoung Hee ,  KIM, Sungsub

Inventor： PARK, Young Woo ,  CHOI, So-Young ,  SONG, Eun-Jung ,  YU, Jung ,  SOHN, Myung-Ho ,  JEON, Jae Won ,  JUNG, Joon-Goo ,  JANG, Myeoung Hee ,  KIM, Sungsub

IPC: C07K16/18

CPC classification number: C07K16/22 ,  C07K2317/21 ,  C07K2317/622 ,  C07K2317/76

Abstract: The present invention relates to a vascular endothelial growth factor (VEGF) -specific human antibody, and more particularly to a human antibody including a complementarity determining region (CDR) and a framework region (FR) derived from a human antibody specifically bound to VEGF. The VEGF- specific human antibody of the present invention may be used in diagnosis of diseases caused by the VEGF-overexpression, classification of the diseases, visualization, treatment, and prognostic evaluation.

Abstract translation: 本发明涉及血管内皮生长因子（VEGF）特异性人抗体，更具体地涉及包含衍生自特异性结合VEGF的人抗体的互补决定区（CDR）和构架区（FR）的人抗体。 本发明的VEGF特异性人抗体可用于诊断由VEGF过表达，疾病分类，可视化，治疗和预后评估引起的疾病。

公开(公告)号：WO2010032899A2

公开(公告)日：2010-03-25

申请号：PCT/KR2008/006116

申请日：2008-10-16

Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY ,  PARK, Young Woo ,  HOE, Kwang-Lae ,  CHOI, So-Young ,  PARK, Ji Hyun ,  SONG, Eun-Jung ,  YU, Jung ,  SOHN, Myung-Ho ,  KIM, Sungsub ,  JANG, Myeoung Hee ,  KIM, Dong-Jin

Inventor： PARK, Young Woo ,  HOE, Kwang-Lae ,  CHOI, So-Young ,  PARK, Ji Hyun ,  SONG, Eun-Jung ,  YU, Jung ,  SOHN, Myung-Ho ,  KIM, Sungsub ,  JANG, Myeoung Hee ,  KIM, Dong-Jin

IPC: C07K16/18

CPC classification number: C07K16/40 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/622

Abstract: The present invention relates to an alpha-endolase (ENO1) -specific human antibody, and more particularly to a human antibody including a complementarity determining region (CDR) and a framework region (FR) derived from a human antibody specifically bound to ENO1. The ENO1-specific human antibody expressed in the various kinds of cancer cells of the present invention may be used in diagnosis of the cancer, classification of the disease, visualization, treatment, and prognostic evaluation.

Abstract translation: 本发明涉及α-端粒酶（ENO1）特异性人抗体，并且更具体地涉及包含互补决定区（CDR）和源自其的框架区（FR）的人抗体 与ENO1特异性结合的人抗体。 在本发明的各种癌细胞中表达的ENO1特异性人抗体可用于癌症的诊断，疾病的分类，可视化，治疗和预后评估。

公开(公告)号：WO2010044506A2

公开(公告)日：2010-04-22

申请号：PCT/KR2008/006614

申请日：2008-11-10

Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY ,  PARK, Young Woo ,  CHOI, So-Young ,  JANG, Young-Soon ,  PARK, Ji Hyun ,  SONG, Eun-Jung ,  YU, Jung ,  SOHN, Myung-Ho ,  JEON, Jae Won ,  JUNG, Joon-Goo ,  KIM, Sungsub ,  JANG, Myeoung Hee

Inventor： PARK, Young Woo ,  CHOI, So-Young ,  JANG, Young-Soon ,  PARK, Ji Hyun ,  SONG, Eun-Jung ,  YU, Jung ,  SOHN, Myung-Ho ,  JEON, Jae Won ,  JUNG, Joon-Goo ,  KIM, Sungsub ,  JANG, Myeoung Hee

IPC: C07K16/18

CPC classification number: C07K16/40 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/00 ,  C12N9/6424

Abstract: The present invention relates to a transmembrane protease, serine (TMPRSS4) -specific human antibody, and more particularly to a human antibody including a complementarity determining region (CDR) and a framework region (FR) derived from a human antibody specifically bound to TMPRSS4. The TMPRSS4- specific human antibody expressed in the various kinds of cancer cells of the present invention may be used in diagnosis of the cancer, classification of the disease, visualization, treatment, and prognostic evaluation.

Abstract translation: 本发明涉及跨膜蛋白酶丝氨酸（TMPRSS4）特异性人抗体，并且更具体地涉及包含互补决定区（CDR）和框架区（FR）的人抗体，所述互补决定区（CDR）和框架区（FR）来源于 与TMPRSS4特异性结合的人抗体。 在本发明的各种癌细胞中表达的TMPRSS4特异性人抗体可用于癌症的诊断，疾病的分类，可视化，治疗和预后评估。